Product image of Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol) supplied by GNH India

Ipramol Steri-Neb

Active Ingredient:
Ipratropium Bromide, Salbutamol
Origin:
EU

Ipramol Steri-Neb (Ipratropium Bromide, Salbutamol)

Ipratropium bromide and salbutamol, the active ingredients in Ipramol Steri-Neb, are bronchodilators presented as a combination inhalation solution for inhalation use. It treats asthma, chronic obstructive pulmonary disease (COPD) and bronchospasm in adults and children as prescribed.

GNH India supplies Ipramol Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Norton Healthcare Ltd T/A Ivax Pharmaceuticals Uk

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ipramol Steri-Neb combines two bronchodilators to relax airway smooth muscle and improve airflow in obstructive lung diseases.

  • Asthma: provides rapid relief of bronchoconstriction and improves symptom control.
  • Chronic obstructive pulmonary disease (COPD): reduces airflow limitation and eases dyspnea during exacerbations.
  • Bronchospasm: quickly reverses acute bronchial tightening caused by allergens or irritants.

How It Works

  • Ipratropium bromide antagonizes muscarinic receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction, while salbutamol stimulates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. The combined action produces additive bronchodilation, enhancing airflow in obstructive airway conditions.

Side Effects

Ipramol Steri-Neb may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Dry mouth: reduced salivary secretion.
  • Cough or throat irritation: local airway irritation.
  • Tremor: mild muscle shaking.
  • Headache: transient cranial discomfort.
  • Palpitations: awareness of heartbeat.
  • Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: worsening airway constriction.
  • Tachycardia or arrhythmia: rapid or irregular heart rhythm.
  • Hypokalemia: low blood potassium levels.
  • Angioedema: swelling of face, lips or throat.
  • Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Chest pain: possible cardiac ischemia.

Precautions & Warnings

When prescribing Ipramol Steri-Neb, clinicians should consider several safety measures.

  • Cardiovascular monitoring: observe heart rate and rhythm, especially in patients with cardiac disease.
  • Use with caution in severe arrhythmias: may exacerbate rhythm disturbances.
  • Avoid in known hypersensitivity: discontinue if allergic reactions occur.
  • Pregnancy and lactation: only use if benefits outweigh potential risks.
  • Caution in patients with hyperthyroidism: increased β2‑agonist sensitivity.
  • Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Ipramol Steri-Neb can interact with other medications, altering its efficacy or safety.

Major Interactions (Avoid)

  • Non‑selective beta‑blockers: may blunt salbutamol’s bronchodilatory effect.
  • Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive episodes.
  • Tricyclic antidepressants: may potentiate cardiovascular side effects.

Moderate Interactions (Monitor Closely)

  • Diuretics: can exacerbate salbutamol‑induced hypokalemia.
  • Theophylline: additive stimulant effect on the heart.
  • ACE inhibitors: may increase cough when combined with inhaled agents.

Frequently Asked Questions

Ipramol Steri-Neb is a combination inhalation solution containing ipratropium bromide and salbutamol. It is used to relieve bronchospasm and improve airflow in patients with asthma, chronic obstructive pulmonary disease (COPD) and other conditions that cause reversible airway narrowing.

The product works by two complementary mechanisms: ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced bronchoconstriction, while salbutamol activates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. Together they produce additive bronchodilation.

The dose of Ipramol Steri-Neb is determined by the prescribing healthcare professional based on the patient’s age, disease severity and response to therapy. Clinicians tailor the number of inhalations or nebulizer volume to achieve optimal bronchodilation.

Safety data in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with a single β2‑agonist such as albuterol, the combination adds an anticholinergic component that can improve bronchodilation in severe COPD and reduce the risk of tachyphylaxis. It offers broader airway relaxation than either agent alone, especially in patients with mixed cholinergic and adrenergic bronchoconstriction.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture and direct sunlight. Do not freeze the solution. Keep the container tightly closed when not in use to maintain sterility.

Ipramol Steri-Neb is delivered by inhalation, typically using a nebulizer or a metered‑dose inhaler as directed by the prescriber. The patient inhales the aerosolized medication deep into the lungs, allowing rapid onset of bronchodilation.

Serious adverse events include paradoxical bronchospasm, significant tachycardia or arrhythmias, severe hypokalemia, angioedema and anaphylactic reactions. Patients should be monitored for these signs, especially after the first doses, and seek immediate medical attention if they occur.

The product is contraindicated in individuals with known hypersensitivity to ipratropium, salbutamol or any excipients. It should also be avoided in patients with severe arrhythmias or uncontrolled cardiovascular disease unless specifically directed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ipratropium Bromide, Salbutamol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT